Protolabs Reports Financial Results for the Third Quarter of 2022
Revenue of $121.7 million in the Third Quarter of 2022; GAAP Earnings Per Share of…
Revenue of $121.7 million in the Third Quarter of 2022; GAAP Earnings Per Share of…
ATLANTA–(BUSINESS WIRE)–Interface, Inc. (Nasdaq: TILE), the global flooring solutions company where everything is certified carbon…
European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in…
Exploring financial and strategic options to fund Phase 2 trials of KIN001 in wet age-related…
REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major…
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, November 4, 2022 – Santhera…
TOKYO, Nov 4, 2022 – (JCN Newswire) – Eisai Co., Ltd. announced today that its…
Silicon Valley, California–(Newsfile Corp. – November 3, 2022) – Verified.com today announces a proprietary identity verification…
TOKYO, Nov 4, 2022 – (JCN Newswire) – Fujitsu Limited today will embark on a…
Local Leadership Appointment Helps Advance Alorica’s Strategy for Transformative Growth in India BENGALURU, India–(BUSINESS WIRE)–#alorica—Alorica…
Perth, Australia, Vancouver, British Columbia and Greenville, North Carolina, Nov 4, 2022 – (ACN Newswire)…
–Company also strengthens Board of Directors with appointments of Luca Santarelli and Michael Tomsicek– BASEL,…
FOLSOM, Calif.–(BUSINESS WIRE)–PowerSchool Holdings, Inc. (NYSE: PWSC) (“PowerSchool” or the “Company”), the leading provider of…
SALT LAKE CITY, Nov. 03, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a…
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology…
● Xanthine Oxidase Inhibition with XRx-008 Blocks Uric Acid Induced Increasein Total Kidney Weight in…
ASH 2022 sponsored programs – UCART123 abstract selected for oral presentation & preclinical data on…
Montrouge, France, November 3, 2022 DBV Technologies Reports Third Quarter Financial Results and Business Update…
PHILADELPHIA, PA, Nov. 03, 2022 (GLOBE NEWSWIRE) — Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or…
Discontinuing development of our NC318 program Advancing clinical pipeline: NC410 combination, NC525, and NC762 Extending…